The relationship between aspirin and long-term survival after stomach

The relationship between aspirin and long-term survival after stomach

Studies have shown that the use of small dose aspirin may reduce the incidence of cancer and mortality, but its effect on the survival of gastric adenocarcinoma is unclear. The foreign team has carried out relevant research to assess whether it can improve the long-term survival after the gastric adenoprosis after gastric gland cancer. Related results were published in Gastric Cancer.

This crowd-based queue study includes patients with Swedish gastric adenocarcinoma in 2006 to 2015, and followed up throughout 2020. 1 year, 2 years, 3 years, and the stomach resection was exposed to a daily low dose (75-160 mg) aspirin and 5 years all done mortality (main ending) and disease-specific mortality. Multivariate COX regression analysis provides a risk ratio (HR) of 95% Credit Interval (CI), the degree of age, gender, education, degree of education, common disease, statin, tumor position, tumor staging, new auxiliary chemotherapy Surgeon and surgical radical surgery of stomach resection surgery.

The study was included in 2025 patients, of which 545 (26.9%) patients used aspirin during surgery. In the patient who took aspirin, 178 people (32.7%) did not take aspirin after surgery. About 56 (2.8%) patients began using Aspirin within one year after stomach resection. 52 (9.5%) aspirin clothing and 91 (6.2%) were died within 90 days of surgery in surgery.

The Kaplan-Meier curve indicates that there is no statistical difference between the survival of taking and unbained aspirin patients.

The use of aspirin within 1 year before surgery did not decrease the risk of 50 years of mortality (HR = 0.98, 95% Ci 0.85-1.13) or the disease-specific mortality (HR = 1.00, 95% CI 0.86-1.17).

It was not reduced the risk of mortality in five years in 2 years (HR = 0.98, 95% CI 0.84-1.15) or 3 years (HR = 0.94, 95% CI 0.79-1.12). Similarly, patients with aspirin in 1 year before surgery have no decrease in death due to death in 5 years (HR = 1.01, 95% CI 0.82-1.25).

In sensitivity analysis, we excluded 291 patients with gastrointestinal exemptions without clear treatment purposes. In the analysis of 1734 patients, 90 days of mortality was 4.0%. Compared with the uncompressed aspirin, taking aspirin and 5 years of mortality (HR = 0.92, 95% Ci 0.78-1.09) or 5 years of disease-specific mortality (adjusted HR = 0.94, 95%) Ci 0.79-1.13) No correlation.

In summary, the study shows that the use of small dose aspirin may not increase the long-term survival rate after stomach adenocarcinomy.

Original source:

. Holmberg D, Kauppila JH, Mattsson F, Asplund J, Leijonmarck W, Xie SH, Lagergren J. Aspirin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma Gastric Cancer 2022 Feb 15. doi:. 10.1007 / s10120-022 --01282-0. Epub Ahead of print.

Tip: The content of this article is for reference only, please refer to the consultation results of regular hospitals! >> https://www.goodmedicals.com/
()